Search

You searched for "SIU"

353 results found

Robotic assisted perineal prostatectomy: descriptive technique of the inaugural case in the UK

1 January 2019 | | URO - Urologic Oncology, URO - Technology
Robotic surgery has taken full flight in the USA since its start in 2000 [1] and is replacing procedures where open surgical techniques were solely employed. While this technology is met with criticism over the costs, the superiority of robotic...

Nocturia – the Cinderella of lower urinary tract symptoms

1 March 2014 | | URO - Functional / Reconstructive Urology
Nocturia is defined as waking during the night (at least once) to urinate. The important part of the definition relates to the necessity of sleep to precede the episode (although whether sleep must follow the episode is less clear). The...

Post radical nephrectomy presenting with skull metastasis

10 April 2024 | | URO - Urologic Oncology
We present the case of an 83-year-old female who underwent right radical nephrectomy for renal cell carcinoma (RCC). Despite negative surgical margins, the patient presented with a skull metastasis six years post radical nephrectomy. This case highlights the importance of...

In conversation with Ian Pearce

21 August 2024 | URO - Core Urology
We were delighted to catch up with our old friend, Ian Pearce, former Editor of Urology News and new President of BAUS. Can you tell us a little bit about what led you into the field of urology and the...

Demanding cases or nightmares in uro-oncology? May/Jun 2022

3 May 2022 | | URO - Urologic Oncology
Delayed diagnosis of testicular cancer Testicular cancer is considered rare in the general population but is the most common cancer affecting males between 24 and 49 years. The diagnosis of testicular cancer depends on physical examination, ultrasound findings and tumour...

So you want to go on a Fellowship: part 1

1 January 2016 | | URO - Core Urology
Look out for part 2 of this series later in 2016 when the author will discuss settling into the research role of his fellowship and will reflect on his first year overseas. This is the first in a series of...

Urology: a missed opportunity for medical students

1 September 2014 | | URO - Core Urology
For those of us lucky enough to have medical students attached to our teams at some time during their undergraduate training, the opportunity undoubtedly represents a refreshing chance to teach well-educated and enthusiastic clinicians at the very start of their...

‘Man van’ launched to speed up cancer diagnosis and improve healthcare access

1 June 2022 | URO - Andrology, URO - Urologic Oncology
The ‘Man Van’, an innovative new outreach programme, was launched in March this year to provide free health checks for men and boost early diagnosis of prostate and other urological cancers. The mobile health clinic will visit workplaces and churches...

Penile Mondor’s disease

1 January 2019 | | URO - Andrology
Mondor’s disease is a rare, self-limiting entity characterised by subcutaneous chord like bands throughout the body. These bands arise due to phlebitis of the subcutaneous vessels. Penile Mondor’s disease (PMD) is an isolated superficial thrombophlebitis of the superficial dorsal vein...

Prostate cancer series: diagnostics 1

8 January 2025 | | URO - Urologic Oncology
- Click here for Part 2 - A 58-year-old male is referred to your rapid access prostate clinic with a prostate specific antigen (PSA) of 6.0ng/ml. He has no lower urinary tract symptoms (LUTS), past medical history (PMH), or family...

A guide to local anaesthetic transperineal prostate biopsy

2 November 2023 | | URO - Urologic Oncology
In the UK, nearly 100,000 men undergo a prostate biopsy annually, a figure projected to double in the next decade [1]. In recent years, we have observed a paradigm shift in urological practice in numerous UK hospitals. The conventional transrectal,...

Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer

8 November 2021 | | URO - Basic Science Research, URO - Urologic Oncology
Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...